Top Page
Hikma Pharmaceuticals
(LSE:HIK)
Hikma Pharmaceuticals (HIK) vs. iShares MSCI United Kingdom ETF (EWC)
Hikma Pharmaceuticals Business Overview & Revenue Model
Hikma Pharmaceuticals Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 3.13B | 2.88B | 2.52B | 2.55B | 2.34B | Gross Profit |
| 1.42B | 1.41B | 1.26B | 1.30B | 1.21B | EBIT |
| 612.00M | 367.00M | 591.00M | 634.00M | 540.00M | EBITDA |
| 787.00M | 791.00M | 485.00M | 744.00M | 654.00M | Net Income Common Stockholders |
| 359.00M | 190.00M | 188.00M | 421.00M | 431.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 213.00M | 229.00M | 292.00M | 450.00M | 347.00M | Total Assets |
| 5.13B | 4.68B | 4.47B | 4.37B | 4.13B | Total Debt |
| 1.31B | 1.19B | 1.28B | 846.00M | 932.00M | Net Debt |
| 1.12B | 986.00M | 1.01B | 420.00M | 609.00M | Total Liabilities |
| 2.81B | 2.47B | 2.32B | 1.91B | 1.99B | Stockholders Equity |
| 2.31B | 2.20B | 2.13B | 2.45B | 2.13B |
| Cash Flow | Free Cash Flow | |||
| 399.00M | 439.00M | 392.00M | 493.00M | 292.00M | Operating Cash Flow |
| 564.00M | 608.00M | 530.00M | 638.00M | 464.00M | Investing Cash Flow |
| -381.00M | -333.00M | -607.00M | -238.00M | -283.00M | Financing Cash Flow |
| -188.00M | -337.00M | -58.00M | -287.00M | -298.00M |
Hikma Pharmaceuticals Technical Analysis
Hikma Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £176.60M | 4.86 | 33.70% | 1.95% | -0.17% | 2591.96% | |
78 Outperform | £36.84B | 25.90 | 8.80% | 1.61% | -0.61% | 39.00% | |
75 Outperform | £4.57B | 16.34 | 15.79% | 2.98% | 5.83% | 83.35% | |
59 Neutral | $355.92M | ― | -5.04% | ― | -1.02% | 67.70% | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% | |
48 Neutral | £338.42M | ― | -369.20% | ― | 4.50% | 74.32% | |
| $39.57B | 3.74 | 13.12% | 5.94% | ― | ― |
Hikma Pharmaceuticals Corporate Events
Hikma Pharmaceuticals PLC has disclosed transactions involving its senior executives, including Executive Chairman Said Darwazah, Executive Vice Chairman Mazen Darwazah, and Non-Executive Director Ali Al-Husry. These transactions involve the grant of a pledge by Darhold Limited over 430,000 ordinary shares of Hikma Pharmaceuticals in favor of EFG International Bank. This move, involving key figures within the company, could have implications for the company’s financial strategies and stakeholder interests.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £2500.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Hikma Pharmaceuticals announced strong medium-term growth guidance for its Group, projecting a 6% to 8% CAGR in revenue and a 7% to 9% CAGR in core operating profit from 2024 to 2027. The company aims to achieve $5 billion in Group revenue by 2030 and is rebranding its Generics business to Hikma Rx, emphasizing its focus on complex prescription medicines. This strategic move and growth projection highlight Hikma’s commitment to sustainable growth and its significant role in the US generic medicines market.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £2500.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Hikma Pharmaceuticals announced that several of its Persons Discharging Managerial Responsibility (PDMRs) acquired ordinary shares in the company through a dividend reinvestment plan. This acquisition, involving key figures such as CEO Riad Mishlawi, reflects a strategic move to strengthen managerial investment in the company, potentially enhancing stakeholder confidence and aligning management interests with shareholder value.
S&P has upgraded Hikma Pharmaceuticals PLC’s long-term issuer credit rating and its $500 million notes to ‘BBB’ from ‘BBB-‘, citing the company’s strong business momentum and stable growth prospects. This upgrade reinforces Hikma’s solid market position and highlights its consistent profitability and cash generation capabilities.
Hikma Pharmaceuticals has announced a preliminary settlement agreement to resolve the majority of antitrust class action lawsuits related to its product Xyrem® (sodium oxybate) in the United States. The agreement, which is subject to court approval, involves Hikma paying up to $50 million in cash. This settlement aims to protect the company’s interests and provide clarity to stakeholders, without admitting any wrongdoing. The settlement highlights Hikma’s commitment to facilitating access to lower-cost generic medicines, potentially impacting its market positioning and stakeholder relations.
Hikma Pharmaceuticals PLC announced a notification regarding transactions by key managerial personnel, including the Executive Chairman, Executive Vice Chairman, and a Non-Executive Director. These transactions involve a pledge of 600,000 ordinary shares by Darhold Limited, a company associated with these executives, in favor of EFG International Bank. This move reflects significant financial maneuvers within the company, potentially impacting its market dynamics and stakeholder interests.
Hikma Pharmaceuticals announced the successful completion of its 2025 Annual General Meeting, where all proposed resolutions were approved by shareholders. Key resolutions included the approval of a final dividend of 48 cents per share, reappointment of PricewaterhouseCoopers as auditors, and re-election of several directors. The approval of these resolutions reflects strong shareholder support and is expected to positively impact the company’s governance and financial strategies.
Hikma Pharmaceuticals has reaffirmed its full-year guidance for 2025, highlighting strong performance across its global operations. The company’s Injectables business is experiencing solid revenue growth, particularly in Europe and MENA, with recent product launches in North America contributing positively. Hikma’s Branded segment is expanding its oncology portfolio in the MENA region through strategic partnerships, while its Generics business is maintaining stable demand. The company is enhancing its manufacturing capabilities in the US and expects overall revenue growth between 4% and 6%, with core operating profit projected to be between $730 million and $770 million. Hikma’s strategic investments in R&D and local manufacturing are expected to sustain its competitive position and drive future growth.
Hikma Pharmaceuticals PLC announced the granting of discretionary share awards under its 2023 Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBP) to key managerial personnel. These awards, which are conditional on continued employment and performance criteria, are designed to align the interests of the company’s leadership with its long-term strategic goals, potentially impacting the company’s operational focus and stakeholder value.
Hikma Pharmaceuticals announced a transaction involving the disposal of shares by Victoria Hull, a Non-Executive Director of the company. The transaction, which involved the sale of 2,777 ordinary shares at a price of £18.00 each, was conducted on the London Stock Exchange, totaling £49,986. This notification is part of compliance with the EU Market Abuse Regulation, reflecting transparency in managerial transactions.
Hikma Pharmaceuticals has released its 2024 Annual Report and Accounts alongside the Notice of the 2025 Annual General Meeting. These documents are now accessible to shareholders via the company’s website and the UK National Storage Mechanism, reflecting Hikma’s commitment to transparency and regulatory compliance. This announcement underscores Hikma’s ongoing efforts to maintain strong communication with its stakeholders and adhere to financial reporting standards, potentially impacting investor confidence and market perception.
Hikma Pharmaceuticals announced the vesting of conditional share awards for several key executives under its Executive Incentive Plan. This move reflects the company’s ongoing commitment to rewarding its leadership team, potentially enhancing managerial stability and aligning executive interests with shareholder value. The shares were acquired without any cost and retained by the executives, indicating confidence in the company’s future performance.
Hikma Pharmaceuticals reported a strong financial performance for 2024, with a 10% growth in core revenue and a 67% increase in reported operating profit. The company’s strategic acquisitions, such as Xellia Pharmaceuticals’ US business, and new partnerships have bolstered its market position, particularly in the injectables and generics segments. Hikma’s continued investment in R&D and business development is expected to drive future growth, with a positive outlook for 2025, including projected revenue growth of 4% to 6%. The company’s robust balance sheet and increased dividend reflect confidence in its future prospects.